Holdings
22
Concentrated
Top 10 weight
77%
Concentration
Active share
-
Style
Equity
100%
Asset allocation
Portfolio
-Sectors
8High-conviction bets
-Top sector wt.
0.0%Cash
Market-cap allocation
Large cap61%
Mid cap37%
Small cap2%
Asset allocation
Equity100%
Top holdings
18.1%
8.2%
7.7%
Divi's Laboratories Ltd.EQUITY
7.7%7.6%
Cipla Ltd.EQUITY
7.6%Laurus Labs Ltd.EQUITY
5.4%Lupin Ltd.EQUITY
5.4%Fortis Healthcare Ltd.EQUITY
4.6%4.5%
Aurobindo Pharma Ltd.EQUITY
4.0%3.1%
Alkem Laboratories Ltd.EQUITY
3.0%Biocon Ltd.EQUITY
2.7%Mankind Pharma Ltd.EQUITY
2.6%Zydus Lifesciences Ltd.EQUITY
2.6%IPCA Laboratories Ltd.EQUITY
2.2%Abbott India Ltd.EQUITY
1.2%Piramal Pharma Ltd.EQUITY
1.0%0.8%
TREPSCASH_EQUIVALENT
0.1%Net Current AssetsCASH_EQUIVALENT
0.0%AI Smart summary
Pros
- Large-cap tilt (61%) - relatively stable.
Cons
- Compact 22-stock portfolio - higher single-stock impact.
- High top-10 concentration (77%).
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in this category.
No peers found in this category.
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
78.6%
21.3%